DENTSPLY SIRONA Inc. XRAY
9.24 USD -0.52 (-5.33%)
At closeNov 13, 2026, 7:44 AM EST
9.26 +0.02 +0.22%
Pre-market · Nov 13, 7:44 AM ET
9.23 Day range 9.76
8.14 52-week range 14.76
- YTD
- -19.16%
- 1 year
- -15.62%
News
seekingalpha.com DENTSPLY SIRONA Inc. (XRAY) Q3 2026 Earnings Call Transcript DENTSPLY SIRONA Inc. ( XRAY ) Q3 2026 Earnings Call November 5, 2026 4:30 PM EST Company Participants Suzanne Hatcher Daniel Scavilla - President, CEO, Interim Principal Financial Officer & Director…
marketbeat.com DENTSPLY SIRONA Q3 Earnings Call Highlights DENTSPLY SIRONA NASDAQ: XRAY lowered its full-year earnings outlook after third-quarter sales fell across its dental businesses, as pressure from European distributor inventory reductions, the Middle…
zacks.com XRAY Stock Declines as Q3 Earnings & Sales Miss Estimates, Outlook Cut DENTSPLY SIRONA's Q3 sales decline 7.6% amid dental weakness, while Wellspect growth provides support. The company lowers its 2026 outlook.
benzinga.com DraftKings Posts Downbeat Q3 Results, Joins Atlassian, Natera And Other Big Stocks Moving Lower In Friday’s Pre-Market Session Stock futures mixed as DraftKings plunged 21% after earnings missed estimates and FY26 guidance was cut; several other stocks also fell premarket.
benzinga.com Dentsply Sirona Q3 2026 Earnings Call Transcript Dentsply Sirona (NASDAQ:XRAY) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to…
benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session Gainers TransMedics Group (NASDAQ:TMDX) stock rose 17.6% to $81.16 during Thursday's after-market session. The company's market cap stands at $2.5 billion. The company's, Q3 earnings came out today.
benzinga.com Dentsply Sirona Lowers FY2026 Adj EPS Guidance from $1.40-$1.50 to $1.20-$1.30 vs $1.55 Est; Narrows FY2026 Sales Guidance from $3.500B-$3.600B to $3.500B vs $3.570B Est Dentsply Sirona (NASDAQ:XRAY) lowers FY2026 Adj EPS guidance from $1.40-$1.50 to $1.20-$1.30 vs $1.55 analyst estimate. Narrows FY2026 sales outlook from $3.500 billion-$3.600 billion to $3.500…
benzinga.com Dentsply Sirona Q3 Adj. EPS $0.29 Misses $0.31 Estimate, Sales $836.000M Miss $862.001M Estimate Dentsply Sirona (NASDAQ:XRAY) reported quarterly earnings of $0.29 per share which missed the analyst consensus estimate of $0.31 by 6.45 percent. This is a 21.62 percent decrease over earnings of…
benzinga.com ServiceNow To Rally Over 26%? Here Are 10 Top Analyst Forecasts For Monday Analysts raised targets for RS, CVLT, SLB, RNG and VEEV; cut targets for XRAY and FUN while maintaining ratings.
benzinga.com Barrington Research Maintains Outperform on Dentsply Sirona, Lowers Price Target to $13 Barrington Research analyst Michael Petusky maintains Dentsply Sirona (NASDAQ:XRAY) with a Outperform and lowers the price target from $15 to $13.
benzinga.com Mizuho Maintains Neutral on Dentsply Sirona, Lowers Price Target to $12 Mizuho analyst Steven Valiquette maintains Dentsply Sirona (NASDAQ:XRAY) with a Neutral and lowers the price target from $14 to $12.- benzinga.com Leerink Partners Maintains Market Perform on Dentsply Sirona, Lowers Price Target to $10 Leerink Partners analyst Michael Cherny maintains Dentsply Sirona (NASDAQ:XRAY) with a Market Perform and lowers the price target from $14 to $10.
benzinga.com Piper Sandler Maintains Neutral on Dentsply Sirona, Lowers Price Target to $12 Piper Sandler analyst Jason Bednar maintains Dentsply Sirona (NASDAQ:XRAY) with a Neutral and lowers the price target from $14 to $12.
benzinga.com Dentsply Sirona Unit Wellspect HealthCare Announces That Its Surity Urinary Management Portfolio May Be Covered By Traditional Medicare For Eligible Beneficiaries When Medically Necessary This milestone represents an important step in expanding access and reducing barriers to at-home management for people affected by severe urinary incontinence in the U.S. The Surity™ portfolio…
benzinga.com BMO Capital Maintains Market Perform on Dentsply Sirona, Lowers Price Target to $10 BMO Capital analyst Vik Chopra maintains Dentsply Sirona (NASDAQ:XRAY) with a Market Perform and lowers the price target from $13 to $10.- benzinga.com Barclays Maintains Underweight on Dentsply Sirona, Raises Price Target to $11 Barclays analyst Glen Santangelo maintains Dentsply Sirona (NASDAQ:XRAY) with a Underweight and raises the price target from $9 to $11.
- benzinga.com Dentsply Sirona Affirms FY2026 Adj EPS Guidance of $1.40-$1.50 vs $1.42 Est; Affirms FY2026 Sales Guidance of $3.500B-$3.600B vs $3.582B Est Dentsply Sirona (NASDAQ:XRAY) affirms FY2026 Adj EPS guidance from $1.40-$1.50 to $1.40-$1.50 vs $1.42 analyst estimate. Affirms FY2026 sales outlook from $3.500 billion-$3.600 billion to $3.500…
- benzinga.com Dentsply Sirona Q2 Adj. EPS $0.52 Beats $0.35 Estimate, Sales $898.000M Beat $889.810M Estimate Dentsply Sirona (NASDAQ:XRAY) reported quarterly earnings of $0.52 per share which beat the analyst consensus estimate of $0.35 by 48.57 percent. This is unchanged from the same period last year. The…
- benzinga.com Piper Sandler Maintains Neutral on Dentsply Sirona, Raises Price Target to $14 Piper Sandler analyst Jason Bednar maintains Dentsply Sirona (NASDAQ:XRAY) with a Neutral and raises the price target from $13 to $14.
- benzinga.com BMO Capital Initiates Coverage On Dentsply Sirona with Market Perform Rating, Announces Price Target of $12 BMO Capital initiates coverage on Dentsply Sirona (NASDAQ:XRAY) with a Market Perform rating and announces Price Target of $12.
- benzinga.com DENTSPLY SIRONA Appoints John Forston CFO, Effective July 20 DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (Nasdaq: XRAY), the world's largest diversified manufacturer of professional dental products and technologies, today announced the…
benzinga.com Wall Street's Most Accurate Analysts Give Their Take On 3 Healthcare Stocks Delivering High-Dividend Yields In turbulent markets, investors turn to dividend-yielding stocks. Here are analyst ratings for high-yielding energy stocks.
benzinga.com Dentsply Sirona Expands Collaboration With Nashville Dental To Expand U.S. Distribution Footprint Dentsply Sirona (NASDAQ:XRAY), the world's largest diversified manufacturer of professional dental products and technologies, today announced the strengthening of its U.S. distribution footprint…- benzinga.com Mizuho Maintains Neutral on Dentsply Sirona, Lowers Price Target to $14 Mizuho analyst Steven Valiquette maintains Dentsply Sirona (NASDAQ:XRAY) with a Neutral and lowers the price target from $16 to $14.
- benzinga.com Dentsply Sirona Q1 2026 Earnings Call Transcript
- benzinga.com Dentsply Sirona Affirms FY2026 Adj EPS Guidance of $1.40-$1.50 vs $1.43 Est; Affirms FY2026 Sales Guidance of $3.500B-$3.600B vs $3.578B Est Dentsply Sirona (NASDAQ:XRAY) affirms FY2026 Adj EPS guidance from $1.40-$1.50 to $1.40-$1.50 vs $1.43 analyst estimate. Affirms FY2026 sales outlook from $3.500 billion-$3.600 billion to $3.500…
- benzinga.com Dentsply Sirona Q1 Adj. EPS $0.27 Misses $0.28 Estimate, Sales $880.000M Beat $842.589M Estimate Dentsply Sirona (NASDAQ:XRAY) reported quarterly earnings of $0.27 per share which missed the analyst consensus estimate of $0.28 by 3.57 percent. This is a 37.21 percent decrease over earnings of…
benzinga.com Earnings Scheduled For May 5, 2026 - benzinga.com Dentsply Sirona Signs Agreement For Atlanta Dental Supply To Start Offering Dentsply's Connected Technology Solutions Portfolio In U.S. As Of Aug. 1 Dentsply Sirona (NASDAQ:XRAY), the world's largest diversified manufacturer of professional dental products and technologies, today announced an enhanced distribution agreement with Atlanta Dental…
benzinga.com Citigroup Initiates Coverage On Dentsply Sirona with Sell Rating, Announces Price Target of $10 Citigroup analyst Daniel Grosslight initiates coverage on Dentsply Sirona (NASDAQ:XRAY) with a Sell rating and announces Price Target of $10.- benzinga.com Dentsply Sirona And Siemens Announce Dental‑Dedicated MRI Trial Data; MAGNETOM Free.Max Dental Edition Validates Specialized Imaging Features Dentsply Sirona and Siemens Healthineers are pleased to announce that the first-ever dental-dedicated MRI1 (ddMRI) system – MAGNETOM Free.Max Dental Edition – has received FDA clearance in the United…
benzinga.com Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 4% Dividend Yields Investors turn to dividend-yielding stocks during market turbulence. Benzinga offers latest analyst ratings and news on high-yielding stocks in the health care sector, including PRGO and PFE.
benzinga.com These Analysts Boost Their Forecasts On Dentsply Sirona Following Q4 Earnings Dentsply Sirona (XRAY) reported mixed Q4 results, missing earnings but beating sales estimates. FY2026 projections below market expectations.- benzinga.com Mizuho Maintains Neutral on Dentsply Sirona, Raises Price Target to $16 Mizuho analyst Steven Valiquette maintains Dentsply Sirona (NASDAQ:XRAY) with a Neutral and raises the price target from $14 to $16.
- benzinga.com Barrington Research Maintains Outperform on Dentsply Sirona, Raises Price Target to $17 Barrington Research analyst Michael Petusky maintains Dentsply Sirona (NASDAQ:XRAY) with a Outperform and raises the price target from $14 to $17.
benzinga.com Bank, Private-Equity Stock Rout Deepens As AI Fears Mount: What's Moving Markets Friday? A sharp banking selloff gripped Wall Street on Friday, compounding a week dominated by concerns over artificial intelligence-driven economic disruption. Hotter-than-expected producer price data added…
benzinga.com Autodesk, Arlo Technologies, Beyond Meat, Netflix And Other Big Stocks Moving Higher On Friday Autodesk Inc (ADSK) rose sharply after beating Q4 earnings & issuing strong guidance. Other gainers include AAOI, NGNE, ARLO, PRAA, BYND, BWIN, PSKY, & DELL.- benzinga.com Wells Fargo Maintains Equal-Weight on Dentsply Sirona, Raises Price Target to $13 Wells Fargo analyst Vik Chopra maintains Dentsply Sirona (NASDAQ:XRAY) with a Equal-Weight and raises the price target from $12 to $13.
- benzinga.com Evercore ISI Group Maintains In-Line on Dentsply Sirona, Raises Price Target to $15 Evercore ISI Group analyst Elizabeth Anderson maintains Dentsply Sirona (NASDAQ:XRAY) with a In-Line and raises the price target from $12 to $15.
benzinga.com Monster Beverage To Rally More Than 8%? Here Are 10 Top Analyst Forecasts For Friday 
benzinga.com Baird Maintains Neutral on Dentsply Sirona, Raises Price Target to $14 Baird analyst Jeffrey Johnson maintains Dentsply Sirona (NASDAQ:XRAY) with a Neutral and raises the price target from $12 to $14.
benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session 
benzinga.com Earnings Summary: Dentsply Sirona Q4 - benzinga.com Dentsply Sirona Sees FY2026 Adj EPS $1.40-$1.50 vs $1.50 Est; Sees Sales $3.500B-$3.600B vs $3.675B Est Dentsply Sirona (NASDAQ:XRAY) is looking for FY2026 Adj EPS of $1.40-$1.50 vs $1.50 analyst estimate. sees sales of $3.500 billion-$3.600 billion vs $3.675 billion analyst estimate.
- benzinga.com Dentsply Sirona Q4 Adj. EPS $0.27 Misses $0.28 Estimate, Sales $961.000M Beat $927.081M Estimate Dentsply Sirona (NASDAQ:XRAY) reported quarterly earnings of $0.27 per share which missed the analyst consensus estimate of $0.28 by 2.88 percent. This is a 3.85 percent increase over earnings of…
- benzinga.com Earnings Scheduled For February 26, 2026
benzinga.com Dentsply Sirona Earnings Preview - benzinga.com Dentsply Sirona Expands Partnership With Burkhart Dental Supply To Distribute Full Digital Technology Portfolio Starting April 1 As of April 1, Burkhart Dental Supply will represent Dentsply Sirona's full portfolio of dental technology solutions in addition to preventive and restorative solutions it already distributes. The…
benzinga.com eBay To Rally More Than 48%? Here Are 10 Top Analyst Forecasts For Thursday 
benzinga.com What 7 Analyst Ratings Have To Say About Dentsply Sirona